How to buy Acumen Pharmaceuticals stock (Acumen Pharmaceuticals)

Acumen Pharmaceuticals is a biotechnology business based in the US. Acumen Pharmaceuticals shares (ABOS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.85 – a decrease of 8.87% over the previous week. Acumen Pharmaceuticals employs 51 staff and has a trailing 12-month revenue of around $329,000.

Our top picks for where to buy Acumen Pharmaceuticals stock

Buy Acumen Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Acumen Pharmaceuticals stock price (NASDAQ: ABOS)

Use our graph to track the performance of ABOS stocks over time.

Acumen Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.85
52-week range	$1.72 - $5.09
50-day moving average more info button	$2.52
200-day moving average more info button	$2.94
Wall St. target price	$10.80
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.38

Is it a good time to buy Acumen Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acumen Pharmaceuticals price performance over time

Historical closes compared with the close of $1.8 from 2024-12-19

1 week (2024-12-13)	-11.33%
1 month (2024-11-21)	-22.08%
3 months (2024-09-20)	-28.00%
6 months (2024-06-21)	-22.08%

1 year (2023-12-21)	-43.04%
2 years (2022-12-21)	-65.52%
3 years (2021-12-21)	7.07
5 years (2019-12-17)	N/A

Acumen Pharmaceuticals financials

Revenue TTM	$329,000
Gross profit TTM	$-32,361,000
Return on assets TTM	-20.99%
Return on equity TTM	-32.83%
Profit margin	0%
Book value	$3.62
Market Capitalization more info button	$107.5 million

TTM: trailing 12 months

Acumen Pharmaceuticals share dividends

We're not expecting Acumen Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Acumen Pharmaceuticals share price volatility

Over the last 12 months, Acumen Pharmaceuticals's shares have ranged in value from as little as $1.715 up to $5.09. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acumen Pharmaceuticals's is 0.039. This would suggest that Acumen Pharmaceuticals's shares are less volatile than average (for this exchange).

To put Acumen Pharmaceuticals's beta into context you can compare it against those of similar companies.

• TRACON Pharmaceuticals (TCON.US): 1.422
• ARCA Biopharma (ABIO.US): 0.895
• Soligenix (SNGX.US): 1.848

Acumen Pharmaceuticals overview

Acumen Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Frequently asked questions

null
What percentage of Acumen Pharmaceuticals is owned by insiders or institutions?
Currently 11.236% of Acumen Pharmaceuticals shares are held by insiders and 78.46% by institutions. How many people work for Acumen Pharmaceuticals?
Latest data suggests 51 work at Acumen Pharmaceuticals. When does the fiscal year end for Acumen Pharmaceuticals?
Acumen Pharmaceuticals's fiscal year ends in December. Where is Acumen Pharmaceuticals based?
Acumen Pharmaceuticals's address is: 427 Park Street, Charlottesville, VA, United States, 22902 What is Acumen Pharmaceuticals's ISIN number?
Acumen Pharmaceuticals's international securities identification number is: US00509G2093